- Home
- OMF vs MIRM Comparison
OMF vs MIRM Comparison
Compare OMF & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMF | MIRM |
|---|---|---|
| Founded | 1920 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.7B |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OMF | MIRM |
|---|---|---|
| Price | $59.25 | $122.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $66.75 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.0M | 945.6K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.25% | N/A |
| EPS Growth | 54.72 | ★ 74.59 |
| EPS | ★ 1.93 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $66.43 | $26.22 |
| Revenue Next Year | $6.97 | $22.04 |
| P/E Ratio | $30.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.78 | $50.25 |
| 52 Week High | $71.93 | $130.00 |
Technical Indicators
Market Signals| Indicator | OMF | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 60.48 |
| Support Level | $55.93 | $88.92 |
| Resistance Level | $61.62 | N/A |
| Average True Range (ATR) | 1.69 | 6.48 |
| MACD | -0.19 | 0.71 |
| Stochastic Oscillator | 54.59 | 68.21 |
Price Performance
Historical ComparisonAbout OMF OneMain Holdings Inc.
OneMain Holdings Inc is a consumer finance company providing loan products to customers through its branch network and the internet. The company provides personal loan products; offers credit cards; offers optional credit insurance and others; offers a customer-focused financial wellness program, and acquisitions and dispositions of assets and businesses. It provides origination, underwriting, and servicing of personal loans to non-prime customers. The company operates in single reportable segment Consumer and Insurance which originates and services personal loans and auto finance loans, offer credit cards, and provide optional credit and non-credit insurance and other optional products through its branch and central operations, as well as digital platform.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.